Caiazza Francesco, Elliott Louise, Fennelly David, Sheahan Kieran, Doherty Glen A, Ryan Elizabeth J
Centre for Colorectal Disease, St. Vincent's University Hospital, Elm Park, Dublin, Ireland.
Biomark Med. 2015;9(4):363-75. doi: 10.2217/bmm.15.5.
Patients with metastatic colorectal cancer have a very poor prognosis. Incorporation of targeted molecular therapies, such as the anti-EGFR receptor monoclonal antibodies cetuximab and panitumumab, into treatment regimens has improved outcomes for patients with wild-type RAS tumors. Yet, response rates remain low and overall survival times are short. Increased understanding of oncogenic signaling pathways within the tumor, and how these are regulated by the inflammatory tumor microenvironment, is a priority to facilitate the development of biomarkers to better guide the use of existing therapies and to develop new ones. Here, we review recent preclinical and clinical progress in the development of biomarkers for predicting response to anti-EGFR therapy in metastatic colorectal cancer.
转移性结直肠癌患者的预后非常差。将靶向分子疗法，如抗表皮生长因子受体（EGFR）单克隆抗体西妥昔单抗和帕尼单抗，纳入治疗方案已改善了野生型RAS肿瘤患者的治疗效果。然而，缓解率仍然较低，总生存时间较短。深入了解肿瘤内致癌信号通路以及这些通路如何受炎性肿瘤微环境调控，是促进生物标志物开发以更好地指导现有疗法使用并研发新疗法的首要任务。在此，我们综述了转移性结直肠癌中预测抗EGFR治疗反应的生物标志物开发方面的近期临床前和临床进展。
